Urolithin A is a compound the body makes from ellagic acid, a polyphenol found in pomegranate, berries and walnuts, but only some people’s gut bacteria produce it in useful amounts. That gap is why brands ask for it as a standalone ingredient rather than relying on pomegranate extract alone.
This guide is for brand owners planning a urolithin A product made in Japan. It covers what the human trials show, who paid for them, regulatory status in major markets, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a urolithin A product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Small trials report improved muscle endurance and strength with urolithin A, but most were designed and funded by the company that developed the ingredient, and headline outcomes did not always reach significance.
| Study | Design | Reported result |
|---|---|---|
| Randomised, placebo-controlled trial (“ATLAS”), Cell Reports Medicine 2022 (PMID 35584623) | Untrained, overweight, middle-aged adults; 500 mg or 1,000 mg/day urolithin A for 4 months | Leg muscle strength improved about 12% and aerobic endurance measures improved versus placebo; the trial’s primary endpoint, peak muscle power, did not reach significance; sponsored by the ingredient’s developer, whose employees and board members were among the authors |
| Randomised, double-blind, placebo-controlled trial, JAMA Network Open 2022 (PMID 35050355) | 66 older adults (mean age 71.7); 1,000 mg/day urolithin A or placebo for 4 months | Muscle endurance (contractions to fatigue) improved significantly more with urolithin A in two muscle groups tested; the co-primary endpoints, 6-minute walk distance and maximal ATP production, did not differ significantly between groups; multiple authors had financial ties (employment, board positions, shareholding, patents) to the ingredient’s developer |
| Randomised, double-blind, placebo-controlled trial, Journal of the International Society of Sports Nutrition 2024 (PMID 39487653) | 20 resistance-trained male athletes; 1,000 mg/day urolithin A for 8 weeks | Maximum voluntary isometric contraction and repetitions to failure improved significantly versus placebo; 1-rep-max bench press and squat increased only modestly and not significantly; no conflict of interest reported |
Three points to keep in view:
- Primary versus secondary outcomes. In both larger trials, the outcome the study was designed to detect first (peak power, or walk distance and ATP production) did not reach statistical significance. The positive results reported widely are secondary measures.
- Funding. Two of the three trials were funded by, and largely authored by employees or board members of, the company that developed urolithin A as a supplement ingredient. Only the smallest trial reported no conflict of interest.
- Size and population. All three trials are small — 20 to 66 participants — and cover different groups (untrained middle-aged adults, older adults, trained male athletes). Results in one group should not be assumed to carry over to another.
Checked against the published abstracts on 25 September 2026.
Market status
Urolithin A is sold in Japan as a food and supplement ingredient by more than one company, has FDA “no questions” GRAS status for specific US food uses, and remains under review as a novel food in the EU.
- United States. The FDA responded “no questions” to a GRAS (Generally Recognized As Safe) notice for urolithin A, covering specific uses such as protein shakes, meal-replacement drinks, nutrition bars and yogurt drinks at defined levels per serving. A GRAS “no questions” letter is not a blanket approval for every food category or amount — check the notice’s specific scope before you formulate for the US.
- European Union. Urolithin A falls under the EU Novel Food Regulation because it lacks a documented history of significant human consumption in the EU before May 1997. An application for its authorisation as a novel food has been submitted and, as of the sources checked, remains under review rather than authorised. It cannot be sold as a novel ingredient in the EU until authorised.
- Japan. Urolithin A, produced from pomegranate ellagic acid by extraction or fermentation, is already sold in Japan as an ingredient in foods and supplements by more than one company. No Foods with Function Claims notification specific to urolithin A was confirmed in this review.
💬 Need an evidence summary for your regulatory adviser that separates each market’s current status from the underlying trials? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe urolithin A by the specific, secondary outcomes the trials actually measured, and disclose that most of that evidence comes from the ingredient’s own developer.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for muscle endurance in small human trials" | "Reverses ageing”, “boosts autophagy” as a health outcome, or disease names |
| ”Contains 500–1,000 mg urolithin A per daily serving” | Implying the primary study endpoints were met when they were not |
| ”Early research, much of it funded by the ingredient’s developer" | "Clinically proven” without naming the study, its funding and its limits |
How urolithin A is formulated
Urolithin A is dosed in the hundreds of milligrams and has low natural bioavailability, so the production method affects both the spec and the claim you can support.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule or tablet | Straightforward for a 500–1,000 mg daily dose | May need a larger capsule size or split dosing |
| Powder in a capsule or sachet | Flexible dosing at the higher end of trial amounts | Taste if used in a drink format |
Decisions that shape the specification:
- Source and production method. Urolithin A for foods is produced either by extraction and bioconversion from pomegranate ellagic acid, or by fermentation. Ask the supplier for its production method, purity and a certificate of analysis.
- Amount per serving. Trials above used 500–1,000 mg/day. Match the amount to a specific study, and disclose which trial and outcome it supports.
- Companion ingredients. Urolithin A is sometimes combined with other mitochondria- or muscle-focused ingredients. Each needs its own check against Japanese food law.
- Your target market’s status. Confirm US GRAS scope and EU novel food status directly with your regulatory adviser before you commit to a market.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Urolithin A produced from pomegranate ellagic acid is already sold as a food ingredient in Japan. Companion botanicals in a combined “healthy ageing” formula need their own check, since some botanicals sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our NMN and CoQ10 guides if you are building a combined formula.
Before you ask for a quotation
A factory can quote accurately once the source, the amount, the form and the packaging are fixed.
- Urolithin A source, production method and certificate of analysis
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging
- Countries you will sell in, and urolithin A’s current status in each, including the US and EU
💬 Ready to design a Japan-made urolithin A product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does urolithin A improve muscle strength?
Small trials in different populations reported improved muscle endurance, and one trial reported about 12% improvement in leg strength. In two of the three trials, the primary endpoint the study was designed to test did not reach significance — the positive results are secondary measures.
2. Who funds urolithin A research?
Two of the main human trials were funded by, and largely authored by employees or board members of, the company that developed urolithin A as a supplement ingredient. Disclose this alongside any result you cite.
3. Is urolithin A approved in the European Union?
Not yet, as of the sources checked. It is classified as a novel food requiring authorisation, and an application remains under review rather than approved.
4. Is urolithin A GRAS in the United States?
The FDA responded “no questions” to a GRAS notice covering specific food and beverage uses at defined levels per serving. That status applies to those specific uses, not to every food category or amount.
5. Is urolithin A sold in Japan?
Yes. It is produced from pomegranate ellagic acid and sold in Japan as a food and supplement ingredient by more than one company.
Sources: “Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults”, Cell Reports Medicine 2022, 3(5):100633 (PMID 35584623); “Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial”, JAMA Network Open 2022, 5(1):e2144279 (PMID 35050355); “Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training”, Journal of the International Society of Sports Nutrition 2024, 21(1):2419388 (PMID 39487653); FDA GRAS Notice response GRN 000791; EU Novel Food catalogue and pending novel food application documentation (food.ec.europa.eu). Checked on 25 September 2026.